Laurus Labs Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Laurus Labs Ltd. on BSE

Load latest

Laurus Labs Ltd.

15 Sep 2017

607.20

0.69%

Company Update

Press Release / Media Release

BSE India

Laurus Labs receives the EIR from USFDA, and also successfully completes the German Regulatory Authority for Unit 2 and WHO inspections for Units 1 & 3.

pdf

Laurus Labs Ltd.

15 Sep 2017

607.20

0.69%

Company Update

Laurus Labs Limited, a leading research and development driven pharmaceutical company has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its Finished Dosage Formulations (FDF) & Active Pharmaceutical Ingredients (API's) manufacturing plant, Unit 2, located at Atchutapuram, Vishakhapatnam, for the inspection completed in May 2017....

pdf

Laurus Labs Ltd.

04 Sep 2017

607.20

0.69%

Company Update

Analyst / Investor Meet Intimation

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of Analyst/Institutional Investor meeting to be conducted on September 5, 2017 are as follows: Date: September 5, 2017 Analyst / Investors: Motilal Oswal Annual Global Investor Conference 2017 Type of Interaction: One-on-One/Group Meetings...

pdf

Laurus Labs Ltd.

29 Aug 2017

607.20

0.69%

Company Update

Analyst / Investor Meet Intimation

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of Analyst/Institutional Investor meeting to be conducted on August 29, 2017 are as follows: Date Analyst / Investors Type of Interaction August 29, 2017 ICICI Securities Investor Conf2017 One-on-One/Group Meetings;...

pdf

Laurus Labs Ltd.

18 Aug 2017, 08:12PM

607.20

0.69%

Company Update

Press Release / Media Release

BSE India

Press release on USFDA Inspection

pdf

Laurus Labs Ltd.

18 Aug 2017, 07:39PM

607.20

0.69%

Company Update

Updates

BSE India

This is to inform you that US Food and Drug Administration (USFDA) completed inspection of our API facilities in Unit 1 and 3 in Parawada, Visakhapatnam, Andhra Pradesh, with two observations. This is a regular surveillance audit by USFDA, and the observations are procedural in nature and no data integrity issues were observed. This is for your information and records please.

pdf

Laurus Labs Ltd.

10 Aug 2017

607.20

0.69%

Result

Press Release On Financial Results

BSE India

Press Release on Financial Results is attached

pdf

Laurus Labs Ltd.

10 Aug 2017

607.20

0.69%

Result

Financial Results-Q1-2018

BSE India

Please find attached herewith the Financial Results for Q1 of 2017-18.

pdf

Laurus Labs Ltd.

03 Aug 2017

607.20

0.69%

Company Update

Results Conference Call On 11Th August 2017 (Not Investors Meet)

BSE India

Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India, will organize a conference call for investors and analysts, on Friday, August 11, 2017 at 02:00 pm IST. The conference call will be initiated with a brief management discussion on the Q1 FY2018 results which will be declared on August 10 2017. This will be followed by an interactive Question & Answer session....

pdf